• Skip to main content
  • Skip to secondary menu
  • Skip to primary sidebar
  • Skip to secondary sidebar
  • Skip to footer

  • Opinion
  • Health IT
    • Behavioral Health
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Patient Engagement
    • Population Health Management
    • Revenue Cycle Management
    • Social Determinants of Health
  • Digital Health
    • AI
    • Blockchain
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • M&A
  • Value-based Care
    • Accountable Care (ACOs)
    • Medicare Advantage
  • Life Sciences
  • Research

Paige Expands PanCancer Detect to Identify Cancer in Over 40 Tissue Types

by Fred Pennic 02/06/2025 Leave a Comment

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

What You Should Know: 

– Paige, a provider of AI-powered pathology solutions, today announced a significant expansion of Paige PanCancer Detect, its groundbreaking cancer detection tool. 

– Originally launched in 2024 with the ability to identify cancer in 17 tissue types, PanCancer Detect now supports over 40 tissue and organ types, thanks to advancements in Paige’s AI foundation models.

AI-Powered Pathology Solution Enhances Diagnostic Accuracy and Efficiency

This expanded capability has been made possible by Virchow V2, one of Paige’s state-of-the-art foundation models trained on an unprecedented dataset of 3 million digitized slides and 1.8 billion parameters. This vast dataset enables PanCancer Detect to accurately identify cancerous tissue across a wider range of samples, improving diagnostic accuracy and efficiency in pathology labs.

Key benefits of Paige PanCancer Detect:

  • Enhanced Efficiency: Automates cancer detection, allowing pathologists to prioritize critical cases and reduce turnaround time.
  • Improved Accuracy: AI-powered analysis helps to identify subtle cancerous changes that may be missed by human review.
  • Quality Control: Flags potential diagnostic discrepancies, minimizing errors and improving the quality of diagnoses.
  • Reduced Resource Constraints: Helps alleviate staffing shortages and workload pressures in pathology labs.

Proven Performance

The initial version of Paige PanCancer Detect has been independently validated in a study assessing 62 challenging cases across 16 tissue types. The study demonstrated the software’s strong performance in identifying cancerous slides, paving the way for its clinical application as a multi-organ screening tool.

Expanding Accessibility

Paige PanCancer Detect is currently available through Paige’s FullFocus image viewer and will soon be accessible through the company’s platform partners, including PathPresenter, Aiforia, Indica Labs, PathAI, and Gestalt. This expanded accessibility will enable more pathology labs to benefit from this innovative AI solution.“By leveraging the tissue-agnostic capabilities of Virchow V2, Paige PanCancer Detect transforms cancer detection into a broad, scalable AI solution that generalizes the concept of ‘cancer’ across tissues,” said Siqi Liu, Director of AI Science at Paige. “This unique approach, originally demonstrated in our research published in Nature Medicine, has shown in our studies to be effective in detecting both rare cancer variants, low-prevalence cancers, and even precancerous lesions—challenges that traditional task-specific AI models often struggle to address.”

  • LinkedIn
  • Twitter
  • Facebook
  • Email
  • Print

Tagged With: Artificial Intelligence, Cancer Detection, Cancer Diagnostics, Oncology

Tap Native

Get in-depth healthcare technology analysis and commentary delivered straight to your email weekly

Reader Interactions

Primary Sidebar

Subscribe to HIT Consultant

Latest insightful articles delivered straight to your inbox weekly.

Submit a Tip or Pitch

Featured Insights

2025 EMR Software Pricing Guide

2025 EMR Software Pricing Guide

Featured Interview

Paradigm Shift in Diabetes Care with Studio Clinics: Q&A with Reach7 Founder Chun Yong

Most-Read

Medtronic to Separate Diabetes Business into New Standalone Company

Medtronic to Separate Diabetes Business into New Standalone Company

White House, IBM Partner to Fight COVID-19 Using Supercomputers

HHS Sets Pricing Targets for Trump’s EO on Most-Favored-Nation Drug Pricing

23andMe to Mine Genetic Data for Drug Discovery

Regeneron to Acquire Key 23andMe Assets for $256M, Pledges Continuity of Consumer Genome Services

CureIS Healthcare Sues Epic: Alleges Anti-Competitive Practices & Trade Secret Theft

The Evolving Role of Physician Advisors: Bridging the Gap Between Clinicians and Administrators

The Evolving Physician Advisor: From UM to Value-Based Care & AI

UnitedHealth Group Names Stephen Hemsley CEO as Andrew Witty Steps Down

UnitedHealth CEO Andrew Witty Steps Down, Stephen Hemsley Returns as CEO

Omada Health Files for IPO

Omada Health Files for IPO

Blue Cross Blue Shield of Massachusetts Launches "CloseKnit" Virtual-First Primary Care Option

Blue Cross Blue Shield of Massachusetts Launches “CloseKnit” Virtual-First Primary Care Option

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

Osteoboost Launches First FDA-Cleared Prescription Wearable Nationwide to Combat Low Bone Density

2019 MedTech Breakthrough Award Category Winners Announced

MedTech Breakthrough Announces 2025 MedTech Breakthrough Award Winners

Secondary Sidebar

Footer

Company

  • About Us
  • Advertise with Us
  • Reprints and Permissions
  • Submit An Op-Ed
  • Contact
  • Subscribe

Editorial Coverage

  • Opinion
  • Health IT
    • Care Coordination
    • EMR/EHR
    • Interoperability
    • Population Health Management
    • Revenue Cycle Management
  • Digital Health
    • Artificial Intelligence
    • Blockchain Tech
    • Precision Medicine
    • Telehealth
    • Wearables
  • Startups
  • Value-Based Care
    • Accountable Care
    • Medicare Advantage

Connect

Subscribe to HIT Consultant Media

Latest insightful articles delivered straight to your inbox weekly

Copyright © 2025. HIT Consultant Media. All Rights Reserved. Privacy Policy |